Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
<h4>Aim</h4>The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.<h4>Methods</h4>All observational studies and randomized contro...
Main Authors: | Xulei Tang, Lin Yang, Zhiyu He, Jingfang Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23284776/pdf/?tool=EBI |
Similar Items
-
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
by: Tarigan TJE, et al.
Published: (2021-01-01) -
Insulin glargine use and breast cancer: a systematic review and meta-analysis
by: Ibrahim Altedlawi Albalawi, et al.
Published: (2019-03-01) -
Effectiveness and safety of insulin glargine detemir analysis in patients with type 1 diabetes: systematic review and meta-analysis
by: Thales B. C. Silva, et al.
Published: (2018-08-01) -
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01) -
Insulin Glargine and Insulin Aspart Overdose With Pharmacokinetic Analysis
by: Christian C.K. Kim, MD, et al.
Published: (2016-01-01)